For: | Mura VL, Tosetti G, Primignani M, Salerno F. Use of non-selective beta blockers in cirrhosis: The evidence we need before closing (or not) the window. World J Gastroenterol 2015; 21(8): 2265-2268 [PMID: 25741132 DOI: 10.3748/wjg.v21.i8.2265] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v21/i8/2265.htm |
Number | Citing Articles |
1 |
Carlo Merkel, Aleksander Krag. Portal Hypertension VI. 2016; : 187 doi: 10.1007/978-3-319-23018-4_20
|
2 |
Yoo Li Lim, Moon Young Kim, Yoon Ok Jang, Soon Koo Baik, Sang Ok Kwon. Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study. Gut and Liver 2017; 11(5): 702 doi: 10.5009/gnl16478
|
3 |
Alana Zulian Terres, Rafael Sartori Balbinot, Ana Laura Facco Muscope, Morgana Luisa Longen, Bruna Schena, Bruna Teston Cini, Gilberto Luis Rost, Juline Isabel Leichtweis Balensiefer, Louise Zanotto Eberhardt, Raul Angelo Balbinot, Silvana Sartori Balbinot, Jonathan Soldera. Evidence-based protocol for diagnosis and treatment of hepatorenal syndrome is independently associated with lower mortality. Gastroenterología y Hepatología (English Edition) 2022; 45(1): 25 doi: 10.1016/j.gastre.2021.02.009
|
4 |
Alana Zulian Terres, Rafael Sartori Balbinot, Ana Laura Facco Muscope, Morgana Luisa Longen, Bruna Schena, Bruna Teston Cini, Gilberto Luis Rost, Juline Isabel Leichtweis Balensiefer, Louise Zanotto Eberhardt, Raul Angelo Balbinot, Silvana Sartori Balbinot, Jonathan Soldera. Evidence-based protocol for diagnosis and treatment of hepatorenal syndrome is independently associated with lower mortality. Gastroenterología y Hepatología 2022; 45(1): 25 doi: 10.1016/j.gastrohep.2021.02.007
|